📰 Bugra Basat News
Bugra Basat News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bugra Basat. Real-time updates on events, politics, business and more.
February 23, 2022
/PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III...
February 23, 2022
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III
February 23, 2022
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, t...
February 9, 2021
First patient to receive first Orpha Labs drug this week 09.02.2021 08:46 Zug-based Orpha Labs AG launched its compassionate use program to make its lead product ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. The Israeli Ministry of Health approved the use. The first patient will receive ORL-101 in Israel this week. Orpha Labs is committed to discovering and developing treatments for ultra-rare diseases. One of these diseases is Leu...
February 8, 2021
(0) First Patient to Receive ORL-101 in Israel This Week BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL -101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel formulation of an ultra-pure L-fucose currently in development for the treatment of LAD II patients. The Israeli Ministry of Health (MOH) approved the use of ORL-101 for LAD-II patients under Orpha...